Skip to main content

Table 1 Characteristic of included studies

From: Conbercept for patients with age-related macular degeneration: a systematic review

Study ID

Study design

Participants

N

Intervention group (N)

Comparison group (N)

Outcomes

Follow-up time after the first treatment (months)

Li YY, 2017 [17]

RCT

wet AMD

54

Conbercept (27)

Conservative treatment (27)

6

Mei HY, 2017 [18]

RCT

wet AMD

66

Conbercept (33)

Conservative treatment (33)

NA

Song W, 2016 [19]

RCT

wet AMD

112

Conbercept (56)

Conservative treatment (56)

6

Liu ZN, 2016 [20]

RCT

wet AMD

40

Conbercept (20)

Ranibizumab (20)

12

Zhang HX, 2016 [21]

RCT

wet AMD

50

Conbercept (25)

Ranibizumab (25)

1

Liu R, 2015 [22]

RCT

wet AMD

60

Conbercept (30)

Ranibizumab (30)

3

Wang NF, 2017 [23]

RCT

wet AMD

76

Conbercept (38)

Ranibizumab (38)

3

Lyu P, 2016 [24]

RCT

wet AMD

84

Conbercept (42)

Ranibizumab (42)

3

Zheng MW, 2017 [25]

RCT

wet AMD

85

Conbercept (42)

Ranibizumab (43)

3

Wang XX, 2015 [26]

RCT

wet AMD

60

Conbercept (30)

Transpupillary thermotherapy (30)

6

Qin MM, 2016 [27]

RCT

wet AMD

82

Conbercept (41)

Transpupillary thermotherapy (41)

3

Li L, 2017 [28]

RCT

wet AMD

86

Conbercept (43)

Transpupillary thermotherapy (43)

6

Zhang X, 2015 [29]

RCT

wet AMD

98

Conbercept (49)

Transpupillary thermotherapy (49)

6

Zhu Y, 2017 [30]

RCT

wet AMD

50

Conbercept (25)

Triamcinolone acetonide (25)

3

He XT, 2015 [31]

RCT

wet AMD

60

Conbercept (30)

Triamcinolone acetonide (30)

3

Han X, 2017 [32]

RCT

wet AMD

70

Conbercept (35)

Triamcinolone acetonide (35)

3

Pan XL, 2017 [33]

RCT

wet AMD

76

Conbercept (38, 42eyes)

Triamcinolone acetonide (38, 38eyes)

12

Yue JL, 2017 [34]

RCT

wet AMD

76

Conbercept (38)

Triamcinolone acetonide (38)

12

  1. RCT randomized controlled trials, AMD age-related macular degeneration, N number of participants, NA not available; the mean change in best-corrected visual acuity from baseline to the third month after the first treatment; the mean change in central retinal thickness from baseline to the last visit; the mean change in plasma level of VEGF from baseline to the last visit; adverse events